LAVAL, Quebec — Bausch+Lomb has begun rolling out Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) to U.S. pharmaceutical distributors.

The Valeant Pharmaceuticals International subsidiary said Vyzulta is slated to become available to patients at pharmacies across the United States in the next few days.

The first prostaglandin analog with one of its metabolites being nitric oxide, Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

“We’re excited that Vyzulta is now available as a treatment option for people suffering from glaucoma,” stated Joseph Papa, chairman and chief executive officer of Valeant. “We remain committed to developing new innovative eye health medicines that can help address current and emerging unmet medical needs, particularly as the global population continues to advance in age.”

Bausch+Lomb announced Food and Drug Administration approval for Vyzulta in November. Vyzulta was licensed on a global basis to Bausch+Lomb by France-based Nicox S.A.